Increased Risk for ESBL-Producing Bacteria from Co-administration of Loperamide and Antimicrobial Drugs for Travelers' Diarrhea

Emerg Infect Dis. 2016 Jan;22(1):117-20. doi: 10.3201/eid2201.151272.

Abstract

Antimicrobial drug treatment of travelers' diarrhea is known to increase the risk for colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae. Among 288 travelers with travelers' diarrhea, the colonization rate without medications was 21%. For treatment with loperamide only, the rate was 20%; with antimicrobial drugs alone, 40%; and with loperamide and antimicrobial drugs, 71%.

Keywords: AMD; ESBL; antibiotic resistance; antibiotics; antidiarrheal; antimicrobial drugs; antimicrobial resistance; diarrhea; extended-spectrum beta-lactamase–producing Enterobacteriaceae; loperamide; travel; travel health; travel medicine; travelers’ diarrhea.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Infective Agents / administration & dosage*
  • Anti-Infective Agents / adverse effects*
  • Diarrhea / drug therapy*
  • Diarrhea / microbiology*
  • Enterobacteriaceae / isolation & purification*
  • Female
  • Humans
  • Loperamide / administration & dosage*
  • Loperamide / adverse effects*
  • Male
  • Risk
  • Travel
  • beta-Lactamases / metabolism

Substances

  • Anti-Infective Agents
  • Loperamide
  • beta-Lactamases